Blair William & Co. IL Reduces Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Blair William & Co. IL reduced its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 6.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 114,400 shares of the company’s stock after selling 7,509 shares during the quarter. Blair William & Co. IL’s holdings in CRISPR Therapeutics were worth $4,503,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. ARK Investment Management LLC increased its stake in CRISPR Therapeutics by 19.7% during the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after purchasing an additional 1,474,439 shares in the last quarter. Baker BROS. Advisors LP increased its position in shares of CRISPR Therapeutics by 743.1% in the 3rd quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock valued at $39,608,000 after acquiring an additional 743,075 shares during the period. State Street Corp raised its stake in CRISPR Therapeutics by 25.0% in the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after acquiring an additional 599,304 shares during the last quarter. Contrarius Group Holdings Ltd acquired a new stake in CRISPR Therapeutics during the 4th quarter worth about $14,516,000. Finally, Raymond James Financial Inc. acquired a new position in shares of CRISPR Therapeutics in the fourth quarter valued at about $3,231,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at CRISPR Therapeutics

In related news, COO Julianne Bruno sold 1,198 shares of the company’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $50,819.16. Following the completion of the sale, the chief operating officer now owns 8,263 shares of the company’s stock, valued at approximately $350,516.46. This represents a 12.66 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Samarth Kulkarni sold 18,360 shares of the firm’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the transaction, the chief executive officer now directly owns 171,613 shares in the company, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 32,381 shares of company stock valued at $1,608,243 over the last 90 days. 4.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

CRSP has been the subject of a number of research reports. Stifel Nicolaus decreased their target price on CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a report on Thursday, February 13th. Morgan Stanley lifted their price objective on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a research note on Friday, February 14th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research note on Friday, March 21st. Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. Finally, Royal Bank of Canada cut their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $73.11.

CRISPR Therapeutics Trading Down 2.8 %

CRSP stock opened at $36.99 on Monday. The business’s 50-day moving average is $43.10 and its 200 day moving average is $45.17. CRISPR Therapeutics AG has a 12-month low of $36.52 and a 12-month high of $68.39. The stock has a market cap of $3.17 billion, a price-to-earnings ratio of -8.46 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. As a group, equities analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.